MARKET

NEOS

NEOS

Neos
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9000
-0.0713
-7.34%
After Hours: 0.8805 -0.0195 -2.17% 19:53 02/25 EST
OPEN
0.9471
PREV CLOSE
0.9713
HIGH
0.9600
LOW
0.9000
VOLUME
1.84M
TURNOVER
--
52 WEEK HIGH
1.620
52 WEEK LOW
0.4501
MARKET CAP
44.78M
P/E (TTM)
-2.0482
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
4 Penny Stocks Nearing 2021 Highs But Are They A Buy Right Now?
Feb 24, 2021 (Penny Stocks via COMTEX) -- Are These On Your List Of Penny Stocks To Buy Or Avoid? This year is off to a roaring start, and penny stocks are...
Penny Stocks · 1d ago
Hercules Capital Reports Fourth Quarter and Full-Year 2020 Financial Results
--Q4 2020 Net Investment Income Provides 116% Coverage of Base Distribution Payout
BusinessWire · 2d ago
ADHD Therapeutics Market: 2021 Global Industry Size, Share, Growth Opportunities, Analysis, Developments Trends, Forecast To 2025
Heraldkeepers · 02/16 10:40
Aytu BioScience Announces Record Fiscal Q2 2021 Net Revenue of $15.1 Million, an Increase of 377% Year-Over-Year
February 11, 2021 (ACCESSWIRE via COMTEX) -- Announced definitive merger agreement with Neos Therapeutics, creating a combined $100 million revenue specialty...
ACCESSWIRE · 02/11 21:01
Attention deficit Hyperactivity Disorder (ADHD) Drugs Market Size 2021, Key Leading Countries with Impact of COVID-19, Industry Analysis by Growth, Share, Trends, Opportunities and Expansion Plans to 2023
Feb 11, 2021 (The Expresswire) -- The Global “Attention deficit Hyperactivity Disorder (ADHD) Drugs Market” report elaborates an in-depth study about the...
The Express Wire · 02/11 06:19
BRIEF-Aytu Bioscience And Neos Therapeutics Announce Special Meetings Of Stockholders Related To Proposed Merger To Be Held On March 18, 2021
reuters.com · 02/10 14:05
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021
- Record date for each Special Meeting of Stockholders is February 5, 2021 -
ACCESSWIRE · 02/10 13:00
Aytu BioScience, Neos Therapeutics Shareholders To Vote on Deal In March
MT Newswires · 02/10 12:48
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NEOS. Analyze the recent business situations of Neos through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NEOS stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 84
Institutional Holdings: 13.44M
% Owned: 27.01%
Shares Outstanding: 49.76M
TypeInstitutionsShares
Increased
6
706.56K
New
16
-4.43M
Decreased
7
2.41M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.83%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/Independent Director
Alan Heller
President/Chief Executive Officer/Director
Gerald McLaughlin
Chief Financial Officer/Treasurer
Richard Eisenstadt
Senior Vice President/General Counsel/Secretary
John Limongelli
Independent Director
Bryant Fong
Independent Director
Beth Hecht
Independent Director
James Robinson
Independent Director
Gregory Robitaille
Independent Director
John Schmid
Independent Director
Linda Szyper
  • Dividends
  • Splits
  • Insider Activity
No Data
About NEOS
Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

Webull offers kinds of Neos Therapeutics Inc stock information, including NASDAQ:NEOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEOS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NEOS stock methods without spending real money on the virtual paper trading platform.